Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | KHK | P50053 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PER2 | O15055 | 5/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | GNRHR | P30968 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14978753 | 0.85 | TP53 (0.42) | TP53KHKLMNAPER2NPY5R | |
| SCHEMBL16169609 | 0.84 | TP53 (0.54) | TP53KHKLMNAPER2HTR2A | |
| SCHEMBL14978022 | 0.80 | TP53 (0.38) | TP53KHKPER2 | |
| SCHEMBL16169603 | 0.79 | TP53 (0.59) | TP53MAPT | |
| Trifluoroacetic Acid SCHEMBL16163152 | 0.79 | TP53 (0.37) | TP53KHKPER2 | |
| SCHEMBL14978693 | 0.74 | TP53 (0.41) | TP53KHKLMNAPER2NPY5R | |
| SCHEMBL16172053 | 0.73 | TP53 (0.42) | TP53KHKLMNAPER2MAPT | |
| SCHEMBL2855094 | 0.73 | TP53 (0.59) | TP53KHKPER2 | |
| SCHEMBL14978752 | 0.71 | BTK (0.41) | TP53LMNA | |
| SCHEMBL21151926 | 0.70 | TP53 (0.43) | TP53KHKPER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | GPR119, UTS2R, GPR139 | TP53 4454/4885KHK 3697/4885LMNA 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.